Core Viewpoint - The company has approved the use of idle raised funds and self-owned funds for cash management and entrusted financial management, ensuring that the normal operation of investment projects and fund safety are prioritized. Group 1: Fund Management Approval - The company convened the 10th meeting of the 8th Board of Directors and the 10th meeting of the 8th Supervisory Board on January 20, 2025, to approve the proposal for cash management using idle raised funds and self-owned funds, with a limit of up to RMB 100 million for raised funds and RMB 150 million for self-owned funds [1][2]. Group 2: Redemption of Financial Products - The company and its wholly-owned subsidiaries have redeemed all principal and income from cash management products and entrusted financial management as of the announcement date [1][7]. Group 3: Approval Process - The proposal for cash management has been approved by both the Board of Directors and the Supervisory Board, with clear consent from the supervisory board and the sponsor institution [2]. Group 4: Financial Impact - As of the announcement date, the company has not exceeded the authorized limit for cash management using idle raised funds and self-owned funds, with a balance of RMB 0 for both categories [7]. Group 5: Documentation of Financial Products - The company has provided documentation for various redeemed financial products, including structured deposits and asset management plans, indicating a diversified approach to cash management [8][9].

Core Viewpoint - The company has approved the use of idle raised funds and self-owned funds for cash management and entrusted financial management, with a total limit of up to RMB 2.5 billion, ensuring the normal operation of investment projects and fund safety [2]. Group 1: Fund Management Approval - The company held the eighth board meeting and the eighth supervisory board meeting on January 20, 2025, where it approved the use of idle raised funds not exceeding RMB 1.0 billion and idle self-owned funds not exceeding RMB 1.5 billion for cash management and entrusted financial management [2][3]. - The investment products chosen are characterized by high safety, good liquidity, and a maturity period not exceeding 12 months [2]. Group 2: Redemption of Financial Products - Recently, the company and its wholly-owned subsidiaries have redeemed all principal and income from cash management and entrusted financial products [2][6]. - The company has disclosed detailed information regarding the redemption of these financial products in various announcements [2]. Group 3: Approval Process - The proposal for using idle funds for cash management was approved by both the board of directors and the supervisory board, with clear consent from the supervisory board and the sponsor institution [3]. Group 4: Financial Impact - As of the announcement date, the company has no outstanding balance of idle raised funds for cash management, and the total usage of self-owned funds for cash management and entrusted financial management is also zero, remaining within the authorized limits set by the board [6].

Group 1 - The company announced on January 16 that it will hold its 15th meeting of the second board of directors on January 15, 2026, to review the proposal for using idle self-owned funds to purchase financial products [1] - The total amount approved for investment in financial products is up to RMB 400 million, which includes the principal [1] - The financial products targeted for investment are low to medium risk with high safety and liquidity, including but not limited to agreed deposits, seven-day notice deposits, structured deposits, large certificates of deposit, income certificates, bond investments, money market fund investments, and entrusted financial management [1] Group 2 - The investment products will have a maturity period of no more than 12 months, and the resolution is valid for 12 months from the date of approval by the board of directors [1] - Within the approved amount and time frame, the company can use the funds in a rolling manner [1]

Core Viewpoint - Luoyang Molybdenum announced the approval of a proposal to use idle self-owned funds for purchasing wealth management or entrusted financial products, with a maximum investment balance of RMB 20 billion [1] Group 1: Proposal Details - The company and its wholly-owned and controlling subsidiaries plan to invest in high-security, high-liquidity financial products, excluding structured deposits [1] - The investment balance for these financial products must not exceed RMB 20 billion (or equivalent foreign currency) and can be rolled over [1] - The proposal is subject to approval at the company's shareholder meeting, with the effective period from the approval date at the 2025 annual shareholder meeting until the 2026 annual shareholder meeting, not exceeding 12 months [1]

Group 1 - The stock price of Fangda Special Steel (600507) closed at 5.9 yuan on January 13, 2026, down by 1.5%, with a turnover rate of 1.18%, a trading volume of 273,200 shares, and a transaction amount of 162 million yuan [1] - On January 13, the net outflow of main funds was 17.52 million yuan, accounting for 10.81% of the total transaction amount, while retail investors had a net inflow of 15.31 million yuan, representing 9.44% of the total transaction amount [2][3] Group 2 - Fangda Special Steel held its first extraordinary general meeting of shareholders in 2026 to review three proposals, including an expected annual related party transaction amount of 778.14 million yuan involving multiple related parties [2] - The company plans to use no more than 1.5 billion yuan of idle funds to purchase government bond reverse repos and low to medium-risk bank wealth management products [2][3] - Fangda Special Steel is applying for a comprehensive credit limit of no more than 14.435 billion yuan, covering various credit businesses such as working capital loans and bank acceptance bills [2]

Core Viewpoint - The company JinHao Medical has reported an increase in stock price and provided updates on the use of idle funds for purchasing financial products, indicating a strategic approach to asset management [1]. Group 1: Stock Performance - As of January 13, 2026, JinHao Medical's stock closed at 26.66 yuan, up 1.21% from the previous trading day [1]. - The stock opened at 26.6 yuan, reached a high of 27.5 yuan, and a low of 26.2 yuan, with a trading volume of 2.4 billion yuan and a turnover rate of 16.12% [1]. Group 2: Financial Product Investment - The company announced the use of up to 100 million yuan of idle self-owned funds to purchase low-risk, high-liquidity bank financial products, approved by the board on October 27, 2025 [1]. - As of January 13, 2026, the remaining balance of the purchased financial products was 60.2 million yuan, representing 16.92% of the company's audited net assets as of the end of 2024 [1]. - The company has added a purchase of 10 million yuan in structured deposits from the Bank of China, with a term of 119 days and an expected annual yield of 0.6% or 1.9%, funded by self-owned capital [1].

Core Viewpoint - The company has approved the use of idle funds for cash management and entrusted financial management, with specific limits set for both categories of funds [1][3]. Group 1: Cash Management - The company has decided to use up to 200 million yuan of idle raised funds for cash management, which can be recycled within 12 months [1]. - Recently, the company has invested 57 million yuan in cash management products using idle raised funds [1]. - The total amount redeemed from cash management products using idle raised funds is 223 million yuan [2]. Group 2: Entrusted Financial Management - The company and its subsidiaries have used a total of 580.08 million yuan of idle self-owned funds for entrusted financial management [3]. - The total amount redeemed from entrusted financial management products using idle self-owned funds is 299.81 million yuan [4]. Group 3: Risk Control Measures - The company selects qualified financial institutions with good credit and financial status for entrusted financial management, ensuring clear contracts and compliance with internal management systems [5]. - Independent directors and the board's audit committee have the authority to supervise and audit the use of funds [5]. Group 4: Impact on Operations - The use of idle self-owned funds for entrusted financial management will not affect the company's main business operations and aims to improve fund efficiency and returns for the company and its shareholders [6]. Group 5: Cumulative Situation - As of the announcement date, the company has no outstanding balance for cash management using raised funds, while the outstanding balance for entrusted financial management using self-owned funds is 821.73 million yuan, all within the approved investment limits [7].

【森鹰窗业8.26亿元闲置资金理财】哈尔滨森鹰窗业股份有限公司（以下简称"森鹰窗业"， 301227.SZ）日前发布现金管理进展公告，截至2025年12月31日，公司及全资子公司使用闲置募集资金 和自有资金进行现金管理的未到期金额合计达8.26亿元，其中闲置募集资金3.46亿元，闲置自有资金 4.80亿元，所有操作均在既定授权额度内。 据悉，2025年5月，森鹰窗业审议通过相关议案，同意使用不超过5亿元闲置募集资金和3亿元闲置自有 资金进行现金管理；同年8月进一步增加2亿元自有资金理财额度，最终自有资金理财额度提升至5亿 元，募集资金额度保持5亿元，资金使用期限自股东大会审议通过之日起至2026年5月15日止，期间可循 环滚动使用。 为防控投资风险，森鹰窗业明确划定投资红线，不购买股票及其衍生品、无担保债券等风险品种。同时 建立多重监督机制，通过跟踪资金运作情况、监事会与独立董事监督、必要时聘请专业机构审计等方 式，确保资金安全。（中经记者 颜世龙 北京报道） ...

为防控投资风险，森鹰窗业明确划定投资红线，不购买股票及其衍生品、无担保债券等风险品种。同时 建立多重监督机制，通过跟踪资金运作情况、监事会与独立董事监督、必要时聘请专业机构审计等方 式，确保资金安全。 （编辑：卢志坤 审核：童海华 校对：陈丽） 中经记者 颜世龙 北京报道 哈尔滨森鹰窗业股份有限公司（以下简称"森鹰窗业"，301227.SZ）日前发布现金管理进展公告，截至 2025年12月31日，公司及全资子公司使用闲置募集资金和自有资金进行现金管理的未到期金额合计达 8.26亿元，其中闲置募集资金3.46亿元，闲置自有资金4.80亿元，所有操作均在既定授权额度内。 据悉，2025年5月，森鹰窗业审议通过相关议案，同意使用不超过5亿元闲置募集资金和3亿元闲置自有 资金进行现金管理；同年8月进一步增加2亿元自有资金理财额度，最终自有资金理财额度提升至5亿 元，募集资金额度保持5亿元，资金使用期限自股东大会审议通过之日起至2026年5月15日止，期间可循 环滚动使用。 ...

南财智讯1月6日电，川发龙蟒公告，公司及子公司拟使用不超过人民币20亿元的暂时闲置自有资金购买 非关联方金融机构发行的安全性高、流动性好的理财产品，包括但不限于结构性存款、短期低风险型理 财产品等。投资期限自董事会审议通过之日起1年内有效，资金可循环滚动使用。该事项已于2026年1月 5日经第七届董事会第十六次会议审议通过，无需提交股东大会审议。 ...